Abstract: Objective To explore the efficacy of transcatheter arterial chemoembolization （TACE） and radion implantation in the treatment of patients with primary liver cancer（PLC） and its impact on hepatic expressions of telomeric repeat binding factor（TRF）1 and TRF2. Methods 108 patients with PLC between December 2013 and December 2015 were recruited in our hospital,and were randomly divided into two groups by tossing coins. 54 patients in the control group received TACE,and another 54 in the observation group received intrahepatic¹²⁵I radion impoantation at the base of TACE. Liver biopsies were conducted and the expressions of TRF1 and TRF2 were stained by SP. Results At the end of 3 months after treatment,the Objective remission rate（ORR） in the combination group was 79.6%,much higher than 61.1% in the TACE-treated group（P<0.05）；serum CEA and AFP levels were （273.7±38.1） ng/ml and （820.4±130.3） μg/L,much lower than （312.5±33.9） ng/ml and （1080.1±121.3） μg/L,respectively,in the TACE group（P<0.01）；the TRF1 expression in the adjacent liver tissue was（9.7±2.3）,much stronger than（4.2±1.8） in the tumorous tissues（P<0.01）,while TRF2 expression in the tumorous tissue was（9.2±2.2）,much stronger than （3.8±2.6） in the adjacent tissue（P<0.01）；the 1 yr-survival in the combination group was much higher than in the TACE group（96.3% vs. 85.2%,x²=3.967,P=0.046）. Conclusion The combination of TACE and hepatic radion implantation in the treatment of patients with PLC is effective,and the mechanism by which it works might be related to the regulation of expressions of TRF1 and TRF2.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radion implantation, Telomeric repeat binding factor 1, Telomeric repeat binding factor 2